Clinical Trials Logo

Clinical Trial Summary

This phase I/II trial studies the side effects and the best dose of stereotactic radiosurgery and to see how well it works in treating patients with large brain metastases. Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the incidence of acute and long-term toxicities with increasing dose of stereotactic radiosurgery (SRS). (Phase I) II. To determine if local control may be improved with increasing doses of SRS. (Phase II) SECONDARY OBJECTIVES: I. To determine the risk of acute and long-term toxicity with increasing dose of SRS. (Phase II) II. To determine if there is increased neurocognitive toxicity with increased dose of SRS. III. To determine the rate of radiation necrosis/steroid dependency. IV. To determine if quality of life is affected more by tumor recurrence versus radiation necrosis. This includes assessment of progression free survival, overall survival, local failure, and number of patients who receive bevacizumab, laser interstitial thermal therapy, or surgery for presumed radiation necrosis. OUTLINE: This is a phase I dose-escalation study followed by a phase II study. Patients undergo SRS guided by computer tomography (CT) and magnetic resonance imaging (MRI). After completion of treatment, patients are followed up at 1-2, 3, 6, 9, and 12 months, every 3 months for 2 years, and then every 4 months thereafter. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01843413
Study type Interventional
Source Case Comprehensive Cancer Center
Contact
Status Suspended
Phase N/A
Start date July 2, 2013
Completion date September 2024

See also
  Status Clinical Trial Phase
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT00098605 - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases Phase 2
Completed NCT00072163 - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma Phase 2
Completed NCT01703507 - Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Phase 1
Completed NCT00033254 - Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases Phase 3
Active, not recruiting NCT01706432 - Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Recruiting NCT01891318 - Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study Phase 1/Phase 2
Completed NCT01276210 - Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases Phase 1
Completed NCT01234740 - Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Phase 1
Completed NCT02312622 - Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer Phase 2
Terminated NCT00937482 - Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer Phase 1
Terminated NCT02269111 - Quantitative MRI in Assessing Disease in Patients With Brain Tumors N/A
Withdrawn NCT02277561 - Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery N/A
Completed NCT00992602 - Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer Phase 2
Withdrawn NCT02145910 - Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases Phase 1